Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition.
Colorectal cancer
Liver metastases
Metachronous
Synchronous
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
26 Dec 2019
26 Dec 2019
Historique:
received:
16
09
2019
accepted:
16
12
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
30
5
2020
Statut:
epublish
Résumé
Approximately 25% of patients with colorectal cancer (CRC) will have liver metastases classified as synchronous or metachronous. There is no consensus on the defining time point for synchronous/metachronous, and the prognostic implications thereof remain unclear. The aim of the study was to assess the prognostic value of differential detection at various defining time points in a population-based patient cohort and conduct a literature review of the topic. All patients diagnosed with CRC in the counties of Stockholm and Gotland, Sweden, during 2008 were included in the study and followed for 5 years or until death to identify patients diagnosed with liver metastases. Patients with liver metastases were followed from time of diagnosis of liver metastases for at least 5 years or until death. Different time points defining synchronous/metachronous detection, as reported in the literature and identified in a literature search of databases (PubMed, Embase, Cochrane library), were applied to the cohort, and overall survival was calculated using Kaplan-Meier curves and compared with log-rank test. The influence of synchronously or metachronously detected liver metastases on disease-free and overall survival as reported in articles forthcoming from the literature search was also assessed. Liver metastases were diagnosed in 272/1026 patients with CRC (26.5%). No statistically significant difference in overall survival for synchronous vs. metachronous detection at any of the defining time points (CRC diagnosis/surgery and 3, 6 and 12 months post-diagnosis/surgery) was demonstrated for operated or non-operated patients. In the literature search, 41 publications met the inclusion criteria. No clear pattern emerged regarding the prognostic significance of synchronous vs. metachronous detection. Synchronous vs. metachronous detection of CRC liver metastases lacks prognostic value. Using primary tumour diagnosis/operation as standardized cut-off point to define synchronous/metachronous detection is semantically correct. In synchronous detection, it defines a clinically relevant group of patients where individualized multimodality treatment protocols will apply.
Sections du résumé
BACKGROUND
BACKGROUND
Approximately 25% of patients with colorectal cancer (CRC) will have liver metastases classified as synchronous or metachronous. There is no consensus on the defining time point for synchronous/metachronous, and the prognostic implications thereof remain unclear. The aim of the study was to assess the prognostic value of differential detection at various defining time points in a population-based patient cohort and conduct a literature review of the topic.
METHODS
METHODS
All patients diagnosed with CRC in the counties of Stockholm and Gotland, Sweden, during 2008 were included in the study and followed for 5 years or until death to identify patients diagnosed with liver metastases. Patients with liver metastases were followed from time of diagnosis of liver metastases for at least 5 years or until death. Different time points defining synchronous/metachronous detection, as reported in the literature and identified in a literature search of databases (PubMed, Embase, Cochrane library), were applied to the cohort, and overall survival was calculated using Kaplan-Meier curves and compared with log-rank test. The influence of synchronously or metachronously detected liver metastases on disease-free and overall survival as reported in articles forthcoming from the literature search was also assessed.
RESULTS
RESULTS
Liver metastases were diagnosed in 272/1026 patients with CRC (26.5%). No statistically significant difference in overall survival for synchronous vs. metachronous detection at any of the defining time points (CRC diagnosis/surgery and 3, 6 and 12 months post-diagnosis/surgery) was demonstrated for operated or non-operated patients. In the literature search, 41 publications met the inclusion criteria. No clear pattern emerged regarding the prognostic significance of synchronous vs. metachronous detection.
CONCLUSION
CONCLUSIONS
Synchronous vs. metachronous detection of CRC liver metastases lacks prognostic value. Using primary tumour diagnosis/operation as standardized cut-off point to define synchronous/metachronous detection is semantically correct. In synchronous detection, it defines a clinically relevant group of patients where individualized multimodality treatment protocols will apply.
Identifiants
pubmed: 31878952
doi: 10.1186/s12957-019-1771-9
pii: 10.1186/s12957-019-1771-9
pmc: PMC6933908
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
228Références
Eur Radiol. 2011 Oct;21(10):2067-73
pubmed: 21617893
Eur J Surg Oncol. 2012 Jan;38(1):16-24
pubmed: 22079259
Liver Int. 2009 Jan;29(1):89-102
pubmed: 18673436
J Chemother. 2010 Oct;22(5):358-63
pubmed: 21123161
Langenbecks Arch Surg. 2007 Sep;392(5):535-8
pubmed: 17294210
Br J Surg. 2014 May;101(6):613-21
pubmed: 24652690
Eur J Surg Oncol. 2004 Oct;30(8):834-41
pubmed: 15336728
Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013
pubmed: 17043279
J Gastrointest Surg. 2005 Feb;9(2):178-86
pubmed: 15694813
Crit Rev Oncol Hematol. 2015 Apr;94(1):122-35
pubmed: 25666309
ANZ J Surg. 2018 May;88(5):445-449
pubmed: 28512795
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
Cancer. 2011 Oct 1;117(19):4484-92
pubmed: 21446046
World J Surg Oncol. 2015 Mar 04;13:92
pubmed: 25889950
J Surg Oncol. 2010 Dec 15;102(8):932-6
pubmed: 21165995
World J Surg Oncol. 2016 Feb 25;14:56
pubmed: 26911142
World J Surg. 2018 Mar;42(3):892-901
pubmed: 28929341
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
J Gastrointest Surg. 2017 Nov;21(11):1831-1840
pubmed: 28884391
Gastroenterol Res Pract. 2018 Jul 11;2018:5353727
pubmed: 30116264
Ann Surg Oncol. 2008 Sep;15(9):2458-64
pubmed: 18463927
J Gastrointest Surg. 2008 Aug;12(8):1399-405
pubmed: 18521698
J Nippon Med Sch. 2006 Apr;73(2):82-8
pubmed: 16641532
Eur Radiol. 2009 Jun;19 Suppl 3:S753-63
pubmed: 19484243
Ann Surg. 2013 May;257(5):800-6
pubmed: 23360920
Ann Surg. 2009 Sep;250(3):440-8
pubmed: 19730175
Ann Surg Oncol. 2014 Apr;21(4):1323-9
pubmed: 24370906
Dig Surg. 2013;30(4-6):293-301
pubmed: 23969407
Nat Rev Clin Oncol. 2014 Aug;11(8):446-59
pubmed: 24889770
Arq Gastroenterol. 2018 Jul-Sep;55(3):258-263
pubmed: 30540088
Surg Oncol. 2013 Mar;22(1):36-47
pubmed: 23253399
Clin Colorectal Cancer. 2014 Jun;13(2):87-93
pubmed: 24373733
Ann Surg Oncol. 2012 Sep;19(9):2860-8
pubmed: 22526903
BMC Cancer. 2014 Nov 04;14:810
pubmed: 25369977
HPB (Oxford). 2013 Feb;15(2):106-15
pubmed: 23297721
HPB (Oxford). 2014 Feb;16(2):101-8
pubmed: 23509899
Ann Surg Oncol. 2007 Feb;14(2):786-94
pubmed: 17103254
Ann Surg Oncol. 2012 Jun;19(6):2035-44
pubmed: 22219066
Br J Surg. 2006 Apr;93(4):465-74
pubmed: 16523446
Arq Gastroenterol. 2012 Dec;49(4):266-72
pubmed: 23329221
Cancer Res. 2013 Apr 1;73(7):2031-43
pubmed: 23536564
J Gastrointest Surg. 2013 Dec;17(12):2133-42
pubmed: 24091909
Oncologist. 2008 Jan;13(1):51-64
pubmed: 18245012
J Surg Oncol. 2018 Apr;117(5):858-863
pubmed: 29611198
World J Surg Oncol. 2018 Jan 5;16(1):3
pubmed: 29304822
Ann Surg Oncol. 2009 Sep;16(9):2395-410
pubmed: 19506963
Br J Surg. 2013 Jul;100(8):1100-7
pubmed: 23696510
Oncol Lett. 2012 Aug;4(2):324-328
pubmed: 22844378
Asian J Surg. 2009 Oct;32(4):189-97
pubmed: 19892621
Int J Colorectal Dis. 2009 Apr;24(4):419-25
pubmed: 19096855
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Br J Surg. 2017 Apr;104(5):580-589
pubmed: 28181674
J Cancer. 2018 May 25;9(12):2167-2174
pubmed: 29937936
Br J Surg. 2011 Sep;98(9):1309-17
pubmed: 21598236
Eur J Surg Oncol. 2008 Feb;34(2):180-4
pubmed: 17983724
J Gastrointest Surg. 2015 Dec;19(12):2192-8
pubmed: 26361773
Eur Radiol. 2016 Nov;26(11):4121-4130
pubmed: 26905871
Clin Colorectal Cancer. 2016 Dec;15(4):e183-e192
pubmed: 27269232
JAMA Surg. 2018 Jul 18;153(7):e180996
pubmed: 29799910
Ann Surg Oncol. 2013 Jan;20(1):295-304
pubmed: 23054102
Br J Cancer. 2007 Dec 17;97(12):1606-12
pubmed: 18071347
Int J Colorectal Dis. 2011 Aug;26(8):967-81
pubmed: 21584664
Colorectal Dis. 2010 Oct;12(10 Online):e229-35
pubmed: 19912286
Eur J Surg Oncol. 2013 Aug;39(8):807-11
pubmed: 23726258